Table 1.
Results of antimicrobial susceptibility tests and genetic characterization.
| Antimicrobial agents | MIC (mg/L) | Interpretation a | Resistance genes | Mutations |
|---|---|---|---|---|
| Aminoglycoside | ||||
| amikacin | >128 | R | aph(3’)-VIb | — |
| gentamicin | >128 | R | aac(3)-IId | |
| kanamycin | >128 | R | ||
| β-lactamb | ||||
| meropenem | >16 | R | bla OXA-58 | — |
| imipenem | >16 | R | bla PER-1 | |
| ertapenem | >16 | R | ||
| cefotaxime | >16 | R | ||
| ampicillin | >128 | R | ||
| aztreonam | >128 | R | ||
| Quinolone | ||||
| ciprofloxacin | >16 | R | — | gyrA (S81L); gyrB(A414T); parC (S84L) |
| Polymyxins | ||||
| colistin | 4 | R | — | pmrC (Q143L, L146F, Q148K, I171V, L258S) |
| Tetracycline | ||||
| tetracycline | >64 | R | RND family efflux pump genes adeDE, adeN-adeIJK, adeL-adeFGH, adeRS-adeAB | |
| Glycylcycline | ||||
| tigecycline | 2 | NA | ||
| Sulfonamide | ||||
| trimethoprim-sulfamethoxazole | >76/4 | R | sul2 | — |
| MLS - Macrolide, Lincosamide and Streptogramin B | ||||
| azithromycin | >64 | R | msr(E); mph(E) | — |
MIC values are categorized as susceptible, intermediate, or resistant following CLSI document M100-S30 or the EUCAST breakpoints. Antimicrobial resistance genes and mutations conferring resistance phenotypes are presented.
aR, resistant; NA, no interpretive criteria are available for Acinetobacter spp. from CLSI, EUCAST or FDA.
bblaADC-25 and blaOXA-51 genes were also detected on the chromosome of the genome, but not in association with an IS.